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Abstract
Background: Alzheimers disease (AD) has been strongly linked to an anomalous self-assembly of the amyloid-b peptide
(Ab). The correlation between clinical symptoms of AD and Ab depositions is, however, weak. Instead small and soluble Ab
oligomers are suggested to exert the major pathological effects. In strong support of this notion, immunological targeting
of Ab oligomers in AD mice-models shows that memory impairments can be restored without affecting the total burden of
Ab deposits. Consequently a specific immunological targeting of Ab oligomers is of high therapeutic interest.
Methodology/Principal Findings: Previously the generation of conformational-dependent oligomer specific anti-Ab
antibodies has been described. However, to avoid the difficult task of identifying a molecular architecture only present on
oligomers, we have focused on a more general approach based on the hypothesis that all oligomers expose multiple
identical epitopes and therefore would have an increased binding to a multivalent receptor. Using the polyvalent IgM
immunoglobulin we have developed a monoclonal anti-Ab antibody (OMAB). OMAB only demonstrates a weak interaction
with Ab monomers and dimers having fast on and off-rate kinetics. However, as an effect of avidity, its interaction with Ab-
oligomers results in a strong complex with an exceptionally slow off-rate. Through this mechanism a selectivity towards Ab
oligomers is acquired and OMAB fully inhibits the cytotoxic effect exerted by Ab(1-42) at highly substoichiometric ratios.
Anti-Ab auto-antibodies of IgM isotype are frequently present in the sera of humans. Through a screen of endogenous anti-
Ab IgM auto-antibodies from a group of healthy individuals we show that all displays a preference for oligomeric Ab.
Conclusions/Significance: Taken together we provide a simple and general mechanism for targeting of oligomers without
the requirement of conformational-dependent epitopes. In addition, our results suggest that IgM anti-Ab auto-antibodies
may exert a more specific protective mechanism in vivo than previously anticipated.
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Introduction
Amyloid is today linked to more than twenty-five different
syndromes, of which the neurodegenerative disorder Alzheimer’s
disease (AD) represents the most prominent example. Amyloid
depositions in AD patients are largely composed of the Ab-
peptide, derived from the proteolytic cleavage of the amyloid
precursor protein (APP). Ab peptides of 39–43 residues all have
clinical relevance, but Ab(1–40) and Ab(1–42) represent the most
abundant variants. Ab(1–42), in particular, has a significantly
higher propensity to aggregate, and has been strongly implicated
in the etiology of AD [1].
Although the histopathological features of Ab depositions
(plaques) are striking, the correlation between Ab depositions and
the clinical symptoms of AD is weak [2]. Small and soluble Ab
assemblies, known as Ab oligomers, correlate better with negative
clinical status and havebeensuggestedto bethe Ab speciesprimarily
responsible for cytotoxicity. The structural features of Ab oligomers
are largely unknown. Ab-targeting immunization, both passive and
active, has been studied in AD mouse models and both types of
immunizations have shown a dramatic improvement regarding
memory and behavior [3,4,5,6,7,8]. Interestingly, passive Ab
vaccination improved cognitive performance within days, without
reducing plaque burden, suggesting that the removal of soluble Ab is
an adequate treatment to restore cognitive function [6].
Ab and its precursor APP has both been suggested to have
important roles concerning neuroprotection and neurotrophicity
[9,10,11]. Therefore, to avoid interfering with the homeostatic
functions of amyloid proteins, a therapeutic approach focused on
clearance of Ab should preferentially target Ab oligomers while
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dependent anti-Ab antibodies, of the IgG isotype, have been
shown to selectively target Ab oligomers, suggesting that an
oligomer-specific architecture exists [12,13,14,15]. However, to
avoid the difficult task of identifying a specific architecture, only
present within the oligomeric form, we have employed a different
rationale based on the assumption that all oligomeric variants of
Ab must expose several similar epitopes. The binding of a
multivalent target to a corresponding multivalent receptor will be
influenced by the avidity that, as opposed to affinity, represents the
product of all single valence interactions. Avidity and affinity are,
however, correlated, as the strength of avidity depends both on the
affinity of each interaction, as well as on the number of
interactions. We propose that an IgM antibody, containing 10
identical binding sites, fulfils the requirements to be a multivalent
receptor for oligomers. We have therefore generated an oligomer-
specific IgM anti-Ab antibody (OMAB) that binds Ab oligomers
with a high specificity and a high affinity, whereas its binding to
Ab monomers and dimers is comparatively weak. OMAB has a
high specificity for oligomeric Ab even in a complex medium
(containing many different forms of Ab), demonstrated by its
ability to completely block, at a highly substoichiometric ratio, the
cytotoxic effects exerted by oligomeric Ab(1–42). The specificity of
a previously identified human anti-Ab IgM antibody (L11.3) was
also evaluated in the current study, and the results were analogous
to those obtained with OMAB, demonstrating a high affinity for
Ab oligomers as compared to Ab monomers and dimers.
Interestingly, anti-Ab auto-antibodies of both IgG and IgM
isotypes are commonly found in the sera of the healthy human
population [16,18,19,20,21,22,23,24]. To further study the Ab
binding pattern of endogenous anti-Ab antibodies having the IgM
isotype, we have screened a set of plasma samples from healthy
donors. These studies found that the isolated endogenous anti-Ab
IgM antibodies all displayed a much higher affinity towards the
oligomeric Ab as compared to monomeric Ab.
Our findings suggest a simple mechanism whereby avid IgM
binding can be used to specifically target oligomeric assemblies of
Ab. With such an approach, antibody binding is not restricted to
specific epitope conformations: the epitope recognized by the IgM
antibody need only be exposed within the oligomeric state.
Moreover, our findings suggest a more specific and possibly
protective role for the abundant spectra of anti-Ab IgM auto-
antibodies present in humans.
Materials and Methods
Ethical statement
The use of all human samples, within this study, was verbally
approved by the donors. The study has been fully anonymized and
no data regarding specific individuals has been recorded. This
implies no possibility to identify and connect specific individuals to
the acquired result. All work and procedures involving human
samples was approved by the Committee of Research involving
Human subjects of the Hebrow University Hadassah medical
school, Jerusalem, Israel, according to the declaration of Helsinki
(permit number: 211-09.02.07). All immunisations of mice was
approved by the Umea ˚ Ethical Board of Animal Research,
Va ¨sterbottens la ¨n, hovra ¨tten o ¨vre norrland, box 384, 901 08,
Umea ˚, Sweden, according to the declaration of Helsinki (permit
number A47-07).
Immunization and cell fusion
Mice (BALB/c, female, 8–10 weeks old) were immunized with
the recombinant Ab(1–40) (Agrisera AB, Va ¨nna ¨s, Sweden). Six
weeks following immunization, sera were tested for antibodies
against Ab. Mice testing positive for anti-Ab antibodies were then
given booster i.v. injections of 50 mgo fA b(1–40). Fusion of
spleenocytes with mouse B-cell myeloma cells was performed 3
days later according to standard procedures and cells were seeded
in 96-well plates at a density of 300 000 cells/well. Selection for
hybrid cells was performed using Dulbecco’s Modified Eagle
Medium/DMEM) with high glucose (4500 mg/L D-Glucose)
containing 10% (v/v) fetal calf serum and hypoxanthine/
aminopterin/thymidine (Gibco). Supernatants from wells with
growing cells were screened for antibodies reactive to Ab. Isotype
determination was performed using the IsoQuick
TM strips for
Mouse Monoclonal Isotyping (Sigma-Aldrich, Germany).
Cell culture
SH-SY5Y neuroblastoma cells were obtained from the
European Collection of Cell Cultures (Center for Applied
Microbiology and Research, Salisbury, Wiltshire, UK). Cells were
cultured in MEM with Earle’s salts (Gibco), supplemented with
10% (v/v) foetal bovine serum, 2 mM L-glutamine (Gibco),
100 units/ml penicillin, 100 mg/ml streptomycin (Gibco), and
1% non-essential amino acid solution (Gibco). Cultures were
maintained in an incubator at 37uC, with a humidified
atmosphere of 5% (v/v) CO2/air.
Cytotoxicity measurement
Ab(1–42) (AlexoTech AB, Umea ˚, Sweden) was dissolved in
10 mM NaOH to 160 mM and further diluted with 4X MEM and
H2O to 40 mM, pH 7.4. The Ab(1–42) sample was further diluted
with 1X MEM to the desired concentration and supplemented
with 2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml
streptomycin (Gibco), 1% MEM non-essential amino acid solution
(Gibco), 1% MEM vitamins solution (Gibco), and 1% MEM
amino acids solution (Gibco). Ab(1–42) was allowed to incubate
with SH-SY5Y cells in the absence or presence of OMAB. Cell
viability was measured after 48 hours using a resazurin reduction
test, a test where blue non-fluorescent resazurin is reduced to pink
highly fluorescent resorufin by living cells [25]. Fluorescence,
directly proportional to cell viability, was measured in each well
with a Tecan Infinite plate reader set to 535 nm excitation and
595 nm emission. Cytotoxicity is presented as a percentage of the
fluorescence of control cells incubated with MEM only. Statistical
analysis was performed using GraphPad Prism version 5.01 for
windows (GraphPad Software, San Diego, California, USA).
Viability of cells incubated with Ab oligomers in the presence or
absence of OMAB was analyzed using One-Way ANOVA with
Dunnett’s post test. Statistical significance was set to a p-value
#0.001.
Oligomer preparation and size-exclusion
chromatography (SEC)
Due to the labile nature of Ab oligomers their preparation must
be carefully monitored. Dissolution of the peptide is perhaps the
most critical step in the procedure where it is of paramount
importance to achieve an effective monomerisation. Presence of
fibrillar seeds otherwise results in an accelerated conversion into
amyloid. There are several methods described in the literature,
where the peptide is dissolved using organic solvents followed by
dilution. However, in our hands these methods frequently result in
impurities where fibrillar seeds prevent population of oligomers.
We have therefore focused on a commonly used alternative where
the peptide is dissolved at high pH followed by adjustment of the
pH using the buffer of choice. Using the cytotoxic potential as
Targeting Ab Oligomers
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tion under cell-culture conditions with respect to Ab concentration
and time of incubation. Ab(1–42) (AlexoTech AB, Umea ˚, Sweden)
was dissolved in 10 mM NaOH to a concentration of 160 mM.
The Ab(1–42) sample was further diluted to 10 mMo r5 0mM (the
higher concentration was used regarding subsequent screen for
human auto-antibodies) in PBS and the pH was adjusted to 7.4.
Following incubation for 1 hour at RT (OMAB) or 2 hours at 4uC
(auto-antibodies), the samples were separated by size-exclusion
chromatography (SEC) (GE Superdex-G75 10/30) at 4uC. To
determine the molecular weight of the Ab species, a gel filtration
protein standard (Bio-Rad) was separated by SEC under the same
conditions as the Ab samples.
Indirect ELISA using OMAB
The OMAB antibody, diluted to 10 mM/ml in PBS, was
adsorbed to Nunc-Immuno MaxiSorp plates (Nunc, Roskilde,
Denmark). Ab-fractions collected from the SEC were allowed to
bind to OMAB plates for 20 minutes at 0uC. Bound Ab was
detected using a polyclonal rabbit anti-Ab antibody (AS08 328,
Agrisera AB, Va ¨nna ¨s, Sweden) at a 1:1000 dilution followed by an
anti-rabbit HRP-conjugated secondary antibody at a 1:5000
dilution (GE healthcare). EC-Blue (Medicago, Uppsala, Sweden)
was used as a substrate for HRP and the signal was detected by
measuring the absorbance at 450 nm. The signal of EC-Blue can
be compared within, but not between plates. Blocking solution and
antibody-dilutions were made with 5% Non-fat dry milk in PBST
and all washes were performed with PBS containing 0.1% Tween-
20 (PBST).
Indirect ELISA using anti-human IgM
The anti-human IgM antibody (Thermo scientific, Rockford,
USA), diluted to 10 mg/ml in PBS, was adsorbed to Nunc-
Immuno MaxiSorp plates (Nunc, Roskilde, Denmark). Human
plasma from eight anonymous healthy donors was diluted 4X in
PBS, added to the wells, and incubated for 1 hour at RT. During
this incubation step, IgM auto-antibodies present in the plasma
were allowed to bind to the anti-IgM antibodies previously
adsorbed to the plate. Ab-fractions collected from the SEC were
thereafter allowed to bind to the IgM auto-antibodies for 20
minutes at 0uC. Detection, blocking, and washes were performed
as described previously.
Epitope mapping and determination of affinity using
surface plasmon resonance (SPR)
The OMAB antibody was immobilized at a density of 10 000–15
000 RU to a CM5 chip (GE Healthcare) using standard amine-
coupling chemistry at pH 6. Analysis of Ab binding was performed
at a flow rate of 50 ml/min in PBS at 25uC. Sensograms were
corrected for non-specific interactions to a reference surface, and by
double referencing [26]. For the determination of affinity constants,
Ab(1–16) was injected at concentrations ranging from 125 nM to
6 mM. The dissociation constant for Ab(1–16) was determined by
fitting the response at the end of each of the association phases to a
single-site binding isotherm. Epitope mapping of OMAB was
performed at a peptide concentration of 5 mM.
Results
Characterization of OMAB
Monoclonal antibodies obtained from hybridomas were
screened for reactivity against different forms of Ab using dot
blots and indirect ELISA (data not shown). A particular clone,
denoted OMAB, fulfilled the requirements of both being of the
IgM isotype and exhibit Ab binding and was therefore
characterized further. Using SPR, a technique that facilitates
detailed monitoring of binding properties, the affinities between
different monomeric Ab fragments and the OMAB antibody were
studied. An interaction was detected between OMAB and Ab(1–
16), Ab(1–22), and Ab(1–40), while no reactivity was seen between
OMAB and Ab(26–40) (Fig. 1A). Similar results were obtained
using ELISA (data not shown). The dissociation rates were
essentially the same for all interactions (except for OMAB with
Ab(26–40)), with a T1/2 corresponding to about 75 s, which
implies a similar, monovalent binding of OMAB to the different
Ab fragments. The reactivity pattern of OMAB suggests that the
Figure 1. OMAB binds to the N-terminus of Ab with an affinity
of 0.5 mM. OMAB was immobilized to a CM5 chip and tested for biding
to (A) Ab peptides of different lengths at a concentration of 5 mM. The
responses were normalized by the molecular weight of each peptide.
(B) Ab(1–16) ranging in concentration from 125 nM to 6 mM. All
experiments were performed in PBS at 25 &degC. The dissociation
constant for Ab(1–16) was determined by fitting the response at the
end of each of the association phases to a single-site binding isotherm.
doi:10.1371/journal.pone.0013928.g001
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16, a flexible portion of the Ab sequence that becomes partly
structured within mature fibrils [27,28]. The dissociation constant
between Ab and OMAB was investigated using monomeric Ab(1–
16), an Ab fragment not prone to aggregate. The dissociation
constant was determined to 0.5 mM by fitting to a single site
binding isotherm (Fig. 1B).
Affinity of OMAB for different Ab assemblies
Ab(1–42) peptides rapidly self-assemble into a range of different
small and soluble oligomers at 37uC in PBS, a reaction easily
monitored using SEC. The predominant species are monomers,
dimers,andtrimers;highermultimersarealsodetected,buttheyare
present at considerably lower concentrations. Using an indirect
ELISA setup where OMAB was probed against various Ab species,
we showed that OMAB exhibited considerable selectivity towards
oligomeric species. OMAB identified oligomeric Ab species with a
molecular weight between 15–100 kDa, but failed to detect the
much more abundant fractions of monomers and dimers (Fig. 2).
The second anti-Ab antibody, AS08 328, used in the indirect
ELISA, binds Ab within the N-terminus, as does OMAB. The N-
terminal localization of these antibodies is a deliberate choice since
the N-terminal part of Ab that remains exposedafter aggregation. It
is important to note that OMAB and AS08 328 competed for Ab to
only a minor extent (20%, data not shown).
Indirect ELISA illustrated the binding pattern of OMAB to Ab,
but failed to elucidate the binding kinetics. Using SPR, the binding
kinetics between OMAB and the different Ab species was
examined. OMAB immobilized on the surface of a biocore
CM5 chip, was probed with different Ab species obtained through
SEC. A dramatic difference in dissociation rates was observed
between the different species. The monomer-dimer fractions
displayed, in accordance with the different monomeric Ab
variants, a very rapid dissociation rate that could be fitted to an
exponential decay function with a T1/2 corresponding to 75 s,
indicating a low binding affinity (Fig. 3a). A considerably stronger
binding was observed to occur between OMAB and the oligomeric
fractions containing Ab(1–40) assemblies of approximately 10–20
Ab peptides. The dissociation rate is clearly bi-modal and a double
exponential decay model was needed for an accurate fit: the initial
rapid phase has a T1/2 of 42s, likely reflecting a partial monovalent
binding, while the second phase has a 5000X slower dissociation
rate, with a T1/2 of 4.2 days (Fig. 3B). These results clearly
illustrate a binding mechanism for OMAB strongly dependent
upon avidity, where a low affinity at each antigen-binding site (i.e.
between a single Ab monomer and the antibody) is compensated
for by an increase in the number of interactions. Regarding the
Ab(1–42) this effect was even more striking where no biphasic
dissociation pattern was noted. The T1/2 of Ab(1–42) monomers
was measured to 57s (Fig. 3C), which is in the same range as
monomeric Ab(1–40). However, the binding between OMAB and
Ab(1–42) oligomers, constituted by approximately 10–20 Ab
peptides, was extremely strong and no dissociation could be noted
throughout the duration of the experiment (Fig. 3D).
The lack of avidity to dimers, and to some extent, trimers may
be explained by the relatively smaller size of these moieties, as the
antigenic aggregate must be large enough to bridge the antigen
binding sites on the IgM molecule.
OMAB binds selectively to Ab fibril ends and inhibits fibril
growth
To further evaluate the binding specificity of OMAB, we
probed its interaction towards mature Ab fibrils. A convenient
method for the monitoring of fibril polymerization in real time is
to immobilize mature Ab(1–40) fibrils on a Biacore CM5 sensor
chip and incubate with an excess of monomeric Ab(1–40) peptide,
an event that will give a continuous propagation of the sensor chip
signal as a result of fibril growth [29]. Upon the addition of
OMAB to the immobilized Ab fibrils, a strong, but highly
substoichiometric binding was detected, which corresponded to a
molar ratio of about 1:2000 OMAB:Ab. This substoichiometric
binding suggested that only a small fraction of the Ab fibrils expose
the epitopes required for OMAB to bind, thus OMAB likely binds
predominantly to exposed fibrillar ends rather than to the lateral
fibril. This hypothesis is supported by the finding that immobilized
fibrils, saturated with OMAB, were unable to bind monomeric Ab
(data not shown). Thus, OMAB effectively inhibited the Ab
polymerization process.
OMAB effectively inhibits the cytotoxicity of Ab in a cell-
viability assay
The cytotoxicity of Ab was studied using a cell-based viability
assay. Freshly prepared Ab(1–42) was added to cultured SH-SY5Y
cells, resulting in 35% of cells remaining viable after 48 hours of
Ab exposure. Co-incubation of Ab and OMAB essentially
eliminated the cytotoxic effect at a substoichiometric OMAB:Ab
ratio corresponding to 1:50 (Fig. 4).
Human IgM auto-antibodies can selectively target the
oligomeric fraction of Ab
Auto-antibodies against Ab are common in humans, and both
IgG and IgM isotypes have been described [16,18,19,20,21,
22,23,24]. In a previous study, an immortalized cell line that
produces an anti-Ab human IgM monoclonal antibody was
established from a healthy human blood donor [17]. This specific
antibody, denoted L11.3, was able to prevent the phenotype of
impaired spatial cognition in aged SAMP mice, similar to previous
findings using IgG antibodies [6,7,30,31]. To compare the binding
properties of the L11.3 antibody with the mouse-derived OMAB,
Figure 2. OMAB selectively reacts with oligomeric Ab. A sample
containing different oligomeric species of Ab(1–42) was separated by
SEC (-). Fractions, collected throughout the SEC, were tested in an
indirect ELISA for reactivity with OMAB (---). In connection to the SEC of
Ab(1–42), a sample containing proteins with known molecular weights
was analyzed. The exclusion volume of the peak maxima of these
proteins is illustrated in the figure (&).
doi:10.1371/journal.pone.0013928.g002
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L11.3 showed a strong selectivity for oligomeric Ab (Fig. 5A).
The reaction pattern of human IgM against Ab was further
studied by investigating plasma from a group of healthy donors.
Similar to both the murine OMAB and the human L11.3
monoclonal antibodies, human plasma IgM bound oligomeric Ab,
while Ab monomers and dimers were omitted (Fig. 5B).
Discussion
Self-assembly of monomeric Ab peptides is a multifactorial
process, where the resulting aggregates can differ in both
morphology and molecular structure. This difference is reflected
in the ability of the different Ab aggregates to exert a pathological
effect. Compelling evidence suggests that small, soluble oligomeric
species, and not large, insoluble aggregates, are the most cytotoxic
Ab species. This hypothesis has been supported by cell-culture
viability assays and through numerous animal experiments, where
several independent investigations have described memory impair-
ment in APP transgenic mice to precede the detection of Ab
depositions [32,33,34,35]. Soluble Ab oligomers, heterogeneous
assemblies vastly ranging in size, were initially described as a soluble
pool of Ab that remained in solution after ultra-centrifugation [36].
This Ab pool was subsequently divided into subfractions from 10 to
100 kDa using filters with different molecular weight cut-offs. To
date, a variety of different soluble Ab species have been
characterized and their physiological effects characterized (for a
recent review, see Shankar et al [37]). Thus, a large accumulation of
Figure 3. A complex between Ab oligomers and OMAB display very slow dissociation rate. Different samples of Ab(1–40) and Ab(1–42)
was separated by SEC. (A) The Ab(1–40) monomeric fraction or (B) Ab(1–40) the oligomeric or (C) monomeric fraction of Ab(1–42) or (D) Ab(1–42) the
oligomeric fraction were analyzed for binding to OMAB, immobilized to a CM5 chip. The dissociation of (A) monomeric Ab(1–40) was fitted to a single
exponential decay (red line) with a rate constant of 0.0092 s and a T1/2 of 75 s, and of (B)(1–40) oligomeric Ab to a double exponential decay (red line)
with rate constants of 0.016 and 1.88 * 10-6, and with a T1/2 of 42 s and 4.2 days, respectively. (C) monomeric Ab(1–42) was fitted to a single
exponential decay (red line) with a rate constant of 0.012 s and a T1/2 of 57 s for the oligomeric fraction of Ab1-42 (D) no dissociation was detected
due to a to very strong interaction. All experiments were performed in PBS at 25uC.
doi:10.1371/journal.pone.0013928.g003
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therapeutic targets.
There are different approaches to the targeting of soluble Ab
oligomers, one approach being immunization. Promising results
have been obtained with both active and passive immunization in
AD mice [3,4,5,6,7,8]. However, active vaccination performed in
human AD patients has, to date, resulted in only moderate clinical
improvements and, in a small number of patients, been associated
with a pathological auto-immune T-cell response resulting in
encephalitis [38]. In this respect passive vaccination may provide a
safer alternative.
Administration of an anti-Ab antibody can reverse spatial memory
deficits in AD mice after only a few days of treatment without
affecting the total burden of deposited Ab [6,39]. These findings
suggest that neuronal death represents a late stage in the pathology of
AD, and that earlier events in the disease may impair neuronal
function without neurodegeneration. If a selective scavenger of Ab
oligomers could be administered at an early stage of the disease, AD-
related brain damage could potentially be reduced.
In a recent publication, monomeric Ab was shown to have a
neuroprotective effect by preventing NMDA-induced exitotoxicity
[10]. This finding is in accordance with previous results showing
that Ab levels increase following brain injury [40,41,42]. This
finding implies that Ab might have an important physiological role
in vivo, a fact that should be considered when designing therapeutic
strategies. It is important that the antibodies used in AD
therapeutics have selective properties, and avoid binding both
monomeric Ab and native APP. Several different oligomer-specific
IgG antibodies have been created to selectively target the specific
fold that only Ab oligomers are believed to possess [12,13,14,15].
To avoid the difficulty of creating an antibody that recognizes a
specific conformational architecture only present within the
oligomers, we have chosen a different approach. Our technique
is based on the rationale that all oligomers are multivalent, i.e. they
potentially expose a number of identical epitopes. An efficient
oligomer-specific receptor should, therefore be multivalent.
However, to facilitate a dynamic screening for oligomers also in
complex solutions in high excess of monomeric species, it is equally
important to have a fast on- and off-rate at each single binding site.
All species of Ab exposing the target sequence will hence have the
same ability to bind but, as a result of the avidity effect, the
dissociation rate will be strongly reduced in oligomeric assemblies.
Thus, the low affinity of each single interaction is compensated by
a high avidity, the product of all single interactions. In other words
the probability that all antigen-antibody interactions will dissociate
simultaneously is exceedingly small therefore, if one interaction is
dissociated, the others will remain associated, thus enhancing the
probability that those dissociated will re-associate.
The multivalent IgM architecture fulfils the criteria of an
effective oligomer receptor. In the current work, we characterized
the oligomer specificity of OMAB, a newly designed monoclonal
Figure 4. OMAB inhibits the cytotoxicity of Ab(1–42) in a
substoichiometric ratio. OMAB was incubated with SH-SY5Y cells in
the presence or absence of Ab(1–42). After 48 hours, cell viability was
detected using resazurin. #=p,0.001 compared to control cells and
*=p,0.001 compared to cells treated with only Ab(1–42).
doi:10.1371/journal.pone.0013928.g004
Figure 5. Human IgM auto-antibodies specifically detect Ab
oligomers. A sample containing different oligomeric species of Ab(1–
42) was separated by SEC (-). Fractions, collected throughout the SEC,
were tested in an indirect ELISA for reactivity with (A) L11.3 (---) or (B)
plasma from eight different human donors (---). Before adding L11.3 or
plasma, the ELISA plate was coated with an anti-human IgM antibody to
ensure that only IgM auto-antibodies were allowed to react with the Ab
species. The level of endogenous anti-Ab antibodies is low in the
plasma and to ensure a measurable response 5X more total Ab was
applied on the SEC column which explains the different elution profiles.
doi:10.1371/journal.pone.0013928.g005
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combination with SEC-separated Ab(1–42), we discovered OMAB
to have a much higher affinity for Ab oligomers than for Ab
monomers and dimers. SPR studies demonstrated that the avidity
effect of OMAB induced a very strong binding to, and a high
selectivity for, Ab oligomers. The most striking effect was seen
when comparing dissociation rates of the different Ab species. The
dissociation rate for Ab monomers and dimers regarding Ab(1–40)
and Ab(1–42) is rapid where T1/2 equals approximately 1 minute
(Fig. 3A and 3C, respectively). On the contrary the corresponding
oligomers, having an apparent size of a 10–20 mer, shows a
dramatic decrease in dissociation rate where T1/2 for Ab(1–40)
equals 4.2 days, while T1/2 regarding Ab(1–42) became to slow to
be measured (Fig. 3B and 3D, respectively).
This finding suggests that the IgM isotype introduces the
potential of multivalent binding, allowing oligomers to bind with a
high affinity, while monomers and dimers bind only transiently
with fast off-rate kinetics. When using IgM antibodies to trap Ab
oligomers, unwanted binding to Ab monomers and APP is, to a
great extent, omitted. It is important to emphasize that the high
selectivity towards oligomers only can be obtained at a relevant
time-scale, if the off-rate at each single binding site is high. A to
high single valence affinity would slow down the process of
identifying oligomers in a large excess of monomeric Ab since the
sites will be blocked by monomers. As a result the ‘‘scanning’’
effect for oligomeric species within the sample would be lost.
A potentially complication of generating oligomer-specific
antibodies is the possible cross-reactivity to mature Ab fibrils.
SPR was used to investigate if OMAB detected amyloid fibrils. We
found that only a small fraction of the OMAB antibody,
corresponding to a molar ratio of 1:2000 OMAB:Ab, bound to
the immobilized amyloid fibrils. We conclude that OMAB is unable
to perform a lateral binding along the Ab fibril, but instead binds to
the more exposed fibrillar ends. This was verified through
competition studies, where OMAB effectively inhibited a continu-
ous polymerization of the fibril upon addition of free Ab monomers.
Specific assemblies of Ab(1–42) efficiently kill human neuronal
cells in culture. Due to the kinetic instability of Ab(1–42) in cell
culture media, the initial oligomeric state of Ab is not maintained
throughout the duration of the experiment. As a consequence, it is
difficult to elucidate the exact size of the cytotoxic Ab assembly, as
well as to determine the molar concentration of cytotoxic Ab.W e
have shown that the addition of OMAB, in a substoichiometric
ratio corresponding to 1:50 (OMAB:Ab monomer), completely
blocks the neurotoxic effect exerted by the Ab(1–42) peptide. This
result also demonstrates the specificity of OMAB in a more
complex matrix.
To date, a detailed characterization regarding the molecular
properties and size of cytotoxic Ab has been lacking. A cytotoxic
effect of Ab-derived diffusible ligands (ADDLs) has been described,
comprising a rather broad spectrum of Ab assemblies [43]. A
cytotoxic effect has also been reported from spheroids, large Ab
assemblies with a molecular weight of 500 kDa [44]. An acute
cytotoxic response is, however, a dramatic cellular effect and, in
vivo, subtler changes may better reflect the pathological events
underlying disease. Essentially all soluble forms of Ab have the
ability to inhibit long-term potentiation (LTP), a cellular correlate
of memory (LTP) [13,45,46,47,48]. LTP is a long-lasting
enhancement in signal transmission between two neurons and is
one of several phenomena underlying synaptic plasticity, the
ability of synapses to change their strength. As the ability to form
memories is thought to be encoded by modifications in synaptic
strength, LTP is considered to be a major cellular mechanism
underlying learning and memory. In AD models, initial observa-
tions correlated impairment in spatial memory with the presence
of Ab nonamers and dodecamers [39], species that are readily
detected by the OMAB antibody. However, impaired LTP, as well
as a decreased dendritic spine density in the hippocampal dentate
gyrus, has been noted prior to the detection of nonamers and
dodecamers [49], suggesting that even smaller Ab assemblies are
able to exert a physiological effect in vivo. Engineered disulphide-
linked dimers of Ab have also been shown to inhibit LTP both in
vitro and in vivo [47]. As OMAB fails to detect assemblies smaller
than a trimer, possibly due to steric hindrance as a result of the
difference in size, alternative smaller binding structures should be
considered to accomplish an oligomer-specific effect targeting e.g.
dimeric species.
The initial events regarding Ab assembly may moreover be
intracellular and design intracellular antibodies, delivered through
an adenoviral vector, have resulted in partial clearance of Ab(1–
42) deposits in a mouse model for AD [50].
The IgM isotype has previously been evaluated in vivo using a
transgenic AD mouse model [17]. Using brain injections of a
human-derived anti-Ab IgM antibody (L11.3), both memory and
learning deficits could be restored. In this study, the injection of
high intravenous doses of the IgM antibody resulted in a fraction
crossing the blood brain barrier and ameliorating the learning
deficiency [17]. In the current investigation, we have evaluated the
binding properties of L11.3 using indirect ELISA and probed it
against a spectrum of different Ab assemblies in parallel with the
murine-derived OMAB. Our results show L11.3 to exhibit a
selectivity for the oligomeric Ab fraction (Fig. 5A), similar to
OMAB, and support the notion that the multiple antigen-binding
sites of IgM induce a high specificity towards oligomeric Ab
assemblies. Epitope mapping of L11.3 demonstrated that antibody
binding occurs within the 16 most N-terminal residues of Ab (data
not shown).
Endogenous autoantibodies against Ab are common in humans
[3,4,5,6,7,8,51,52] and passive immunization using total isolate of
human immunoglobulins, given to AD individuals has resulted in a
slight cognitive improvement [53,54]. Intriguingly, IgM anti-Ab
autoantibodies are found in essentially all individuals, although in
different concentrations [17,18,23]. These human IgM autoanti-
bodies have previously been studied with the aim of identifying
differences between healthy controls and individuals affected by
mild cognitive impairment or AD [18,23]. Differences in IgM
auto-antibodies have been suggested as a potential diagnostic
marker, as the levels of specific IgM auto-antibodies were lower in
AD patients compared to controls [18]. Interestingly also a
catalytic degradation of Ab has been described from IgM
autoantibodies [20,55]. However, regarding OMAB no such
effect could be noted, data not shown.
All plasma samples from young healthy individuals screened by
an indirect ELISA contained anti-Ab IgM auto-antibodies with a
strong preferential binding to oligomers as compared to monomers
and dimers (Fig. 5B). The fact that these antibodies are
ubiquitously present in normal plasma suggests that they have a
possible role in the normal homeostasis of Ab. The L11.3 antibody
is derived from an Epstein-Barr virus immortalized cell line
established from B lymphocytes of a healthy individual. Thus,
L11.3 resembles an anti-Ab antibody naturally present in the sera
of healthy humans. Our finding that OMAB, L11.3, and, IgM
auto-antibodies from eight plasma samples showed a very high
selectivity towards Ab oligomers suggests that human IgM auto-
antibodies may confer a protective effect in vivo, both normally and
when used for AD passive immune therapy.
The current work proposes that the IgM molecule provides an
efficient architecture for the selective trapping of Ab oligomers.
Targeting Ab Oligomers
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e13928The mechanism is mediated by the combined effect of avidity and
a high on and off-rate at each single binding site. Taken together
this generates an efficient, selective and also general mode of
screening for oligomers. Once the oligomeric form is bound the
interaction, as a result of avidity, becomes very strong. Through
this mechanism antibody binding to monomers and precursor
proteins like APP can be minimized. We also show that oligomer
specificity appears to be a general feature of common human anti-
Ab IgM autoantibodies. A more extensive analysis comparing the
oligomer specificity of natural occurring IgM anti-Ab antibodies
between groups of healthy donors and AD patients is currently
ongoing.
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